Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.94 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.71 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.55 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.50 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.48 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 2/20 | 0.71 |
| ▸ | CD44 | P16070 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.46 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.46 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.46 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12505041 | 0.97 | HTR2C (0.89) | HTR2CPNMTCD44MAOBDRD2 | |
| SCHEMBL175146 | 0.97 | HTR2C (1.00) | HTR2CPNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL12803776 | 0.95 | HTR2C (0.84) | HTR2CPNMTCD44MAOBDRD2 | |
| Ammonia Solution, Strong SCHEMBL20359164 | 0.94 | HTR2C (0.94) | HTR2CPNMTCD44MAOBDRD2 | |
| SCHEMBL23555058 | 0.94 | HTR2C (0.94) | HTR2CPNMTCD44MAOBDRD2 | |
| Methyl Alcohol SCHEMBL12803778 | 0.92 | HTR2C (0.80) | HTR2CPNMTCD44MAOBDRD2 | |
| SCHEMBL4503593 | 0.87 | HTR2C (0.80) | HTR2CPNMTCD44MAOBDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 | 0.87 | PNMT (0.95) | HTR2CPNMTCD44MAOBPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL987515 | 0.87 | PNMT (0.95) | HTR2CPNMTCD44MAOBPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29457586 | 0.87 | PNMT (0.95) | HTR2CPNMTCD44MAOBPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150976-A1 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | UNIVERSITY OF ROCHESTER (US) | 2023-05-18 | — | — | US | disclosed |
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | U.S. DEPARTMENT OF ENERGY | 2019-05-23 | — | — | US | disclosed |
| CN-106478506-B | The preparation method of half light green Ka Selin hydrochloride | 山东科兴生物制品有限公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2015102017-A1 | PROCESSES FOR THE PREPARATION OF LORCASERIN | CADILA HEALTHCARE LIMITED (IN) | 2015-07-09 | — | — | WO | disclosed |
| WO-2011153206-A1 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1751163-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20020123488-A1 | Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-05 | — | — | US | disclosed |
| WO-2002051418-A1 | TETRAHYDRO-(BENZO OR THIENO)-AZEPINE-PYRAZINE AND TRIAZINE DERIVATIVES AS MGLUR 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | WO | disclosed |
| US-6218385-B1 | FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS | HOFFMANN-LA ROCHE INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1074549-A2 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| JP-2001019676-A | PRODUCTION OF CYCLIC AMINO COMPOUND | TAKEDA CHEM IND LTD | 2001-01-23 | — | — | JP | disclosed |
| EP-0934068-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998009630-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-12 | — | — | WO | disclosed |
| US-5663183-A | CEREBRAL DISORDERS | SYNTHELABO (FR) | 1997-09-02 | — | — | US | disclosed |
| US-5550162-A | TREATMENT AND PREVENTION OF CEREBRAL DISORDERS | SYNTHELABO (FR) | 1996-08-27 | — | — | US | disclosed |
| EP-0103961-B1 | ALLYLOXY- AND ALLYLTHIO-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | ACHE, BCHE, CHAT | HTR2C 2919/4885MAOB 171/4885DRD2 3520/4885 |
| US-20020123488-A1 | Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine | GRM5, GRIK5, GRM1 | HTR2C 40/4885MAOB 1474/4885DRD2 78/4885 |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | DRD3, DRD2, SLC6A3 | HTR2C 34/4885MAOB 202/4885DRD2 2/4885 |
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | ACHE, BCHE, CHAT | HTR2C 2919/4885MAOB 171/4885DRD2 3520/4885 |
| US-20230150976-A1 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | KDM3B, KDM4D, KDM3A | HTR2C 1469/4885MAOB 2686/4885DRD2 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.